SCHEMBL1363734

SCHEMBL1363734

[CH2]C(C)N1CCOCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5709839 0.78
SCHEMBL11502069 0.78 CYP2D6 (0.32)
SCHEMBL8648295 0.77
SCHEMBL1609019 0.77 KCNA5 (0.37)
SCHEMBL21954031 0.77 HRH3 (0.38)
SCHEMBL13066097 0.77 KCNA5 (0.37)
SCHEMBL57306 0.77
Hydrochloric Acid SCHEMBL27493048 0.76 PKM (0.33)
SCHEMBL24590305 0.74 SMN1; SMN2 (0.40)
SCHEMBL5962431 0.74 SMN1; SMN2 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228525-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects ARBOR PHARMACEUTICALS, LLC 2021-07-29 US claimed
CN-107849024-A With as indoleamine 2, the benzimidazole and imidazopyridine imido of 3 dioxygenase inhibitor activities are for benzamide compound 吉利德科学公司 2018-03-27 CN claimed
EP-2887934-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XenoPort, Inc. (US) 2015-07-01 EP claimed
US-20140364604-A1 METHOD OF MAKING MONOMETHYL FUMARATE HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT 2014-12-11 US claimed
US-20140350018-A9 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-11-27 US claimed
US-20140057917-A1 Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects XENOPORT, INC. (US) 2014-02-27 US claimed
WO-2014031844-A1 METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS XENOPORT, INC. (US) 2014-02-27 WO claimed
US-8569484-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2013-10-29 US claimed
US-20120122817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2012-05-17 US claimed
WO-2010142978-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-16 WO claimed
WO-2010136817-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-12-02 WO claimed
US-7101868-B2 Substituted arylamine derivatives and methods of use AMGEN INC. (US) 2006-09-05 US claimed
EP-1583744-A2 SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE Amgen Inc. (US) 2005-10-12 EP claimed
US-20050203092-A1 4-Pyrimidinamine derivatives, pharmaceutical compositions and related methods BENJAMIN ELFRIDA R (US) 2005-09-15 US claimed
US-20040204437-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2004-10-14 US claimed
WO-2004007457-A2 SUBSTITUTED BENZYLAMINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2004-01-22 WO claimed
US-20030134836-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2003-07-17 US claimed
EP-0063747-B1 2-SUBSTITUTED OR UNSUBSTITUTED AMINOCARBONYLOXYALKYL-1,4-DIHYDROPYRIDINES BANYU PHARMACEUTICAL CO., LTD. (JP) 1987-12-09 EP claimed
US-4404378-A HYPOTENSIVE AGENTS; VASODILATION BANYU PHARMACEUTICAL CO., LTD. (JP) 1983-09-13 US claimed
EP-0063747-A1 2-Substituted or unsubstituted aminocarbonyloxyalkyl-1,4-dihydropyridines BANYU PHARMACEUTICAL CO., LTD. (JP) 1982-11-03 EP claimed